Table 2.
Association of DR-DQ haplotype combinations with C-peptide, AAD, and T1D risk
| Haplotype combination | Frequency | T1D risk | C-peptide | AAD | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SDRNT1BIO | GS | β | SE | P | β | SE | P | Direction* | Het I2 | Het P | β | SE | P | Direction* | Het I2 | Het P | |
| DR3/X | 0.186 | 0.164 | 1.53 | 0.09 | 2.E–70 | −0/08 | 0.06 | 0.16 | + + − − | 66.90 | 0.03 | −0.23 | 0.06 | 6.96E-05 | − − + − − | 43.10 | 0.13 |
| DR3/DR3 | 0.130 | 0.028 | 3.25 | 0.13 | 2.E–129 | −0.04 | 0.07 | 0.58 | + + + − | 49.20 | 0.12 | −0.25 | 0.07 | 1.14E-04 | − − − − + | 6.40 | 0.37 |
| DR3/DR4 | 0.270 | 0.058 | 2.92 | 0.09 | 1.E–216 | −0.01 | 0.05 | 0.92 | + + − − | 62.90 | 4.43E-02 | −0.52 | 0.05 | 7.68E-22 | − − − − − | 82.10 | 1.69E-04 |
| DR4/X | 0.229 | 0.174 | 1.36 | 0.07 | 2.E–77 | −0.08 | 0.05 | 0.12 | − + − − | 58.30 | 0.07 | −0.29 | 0.05 | 1.67E-07 | − − − − − | 44.40 | 0.13 |
| DR4/DR4 | 0.079 | 0.028 | 2.11 | 0.11 | 9.E–85 | −0.02 | 0.07 | 0.74 | + − + − | 22.50 | 0.28 | −0.25 | 0.07 | 3.43E-04 | − − + − − | 0.00 | 0.49 |
| DR3/DR15 | 0.007 | 0.052 | −0.48 | 0.2 | 2.E–02 | 0.34 | 0.23 | 0.13 | + + − + | 35.80 | 0.20 | 0.39 | 0.20 | 0.05 | + + 0 + ? | 19.20 | 0.29 |
| DR4/DR15 | 0.009 | 0.058 | −0.66 | 0.18 | 2.E–04 | 0.48 | 0.16 | 2.00E-03 | + + + + | 40.70 | 0.17 | 0.13 | 0.15 | 0.40 | + + − − + | 0.00 | 0.76 |
| DR15/X | 0.011 | 0.163 | −1.42 | 0.15 | 4.E–20 | 0.84 | 0.16 | 3.95E-07 | + + − + | 73.40 | 1.04E-02 | 0.53 | 0.15 | 2.56E-04 | + + − + ? | 80.50 | 1.49E-03 |
| DR15/DR15 | 0.001 | 0.029 | −1.97 | 0.46 | 2.E–05 | 2.27 | 0.63 | 3.02E-04 | + ? + ? | 0.00 | 0.83 | 0.25 | 0.46 | 0.58 | + ? + ? ? | 0.00 | 0.57 |
| X/X | 0.079 | 0.246 | Reference | Reference | Reference | ||||||||||||
Het, heterogeneity.
*The order of studies for the C-peptide analysis is SDRNT1BIO, DCCT, CACTI, and WESDR, and for AAD, the order is SDRNT1BIO, DCCT, CACTI, WESDR, and EDC.